NCT04480372View on ClinicalTrials.gov

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

March 10, 2023

Study Completion Date

April 3, 2024

Conditions
Malignant Pleural MesotheliomaNon-small Cell Lung Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).

DRUG

Atezolizumab

Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).

Trial Locations (12)

1211

Hôpitaux Universitaires de Genève, Geneva

1752

HFR Fribourg, Fribourg

3010

Inselspital, Bern

4031

Universitaetsspital Basel, Basel

5404

Kantonsspital Baden, Baden

8091

UniversitätsSpital Zürich, Zurich

CH-5001

Kantonsspital Aarau, Aarau

Unknown

St. Claraspital, Basel

CH-7000

Kantonsspital Graubuenden, Chur

CH-9007

Kantonsspital St. Gallen, Sankt Gallen

CH-8400

Kantonsspital Winterthur, Winterthur

CH-8032

Klinik Hirslanden Onkozentrum Zürich, Zurich

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT04480372 - SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | Biotech Hunter | Biotech Hunter